User talk:Innerstream

Welcome!

Hello, Innerstream! Welcome to Wikipedia! Thank you for your contributions. You may benefit from following some of the links below, which will help you get the most out of Wikipedia. If you have any questions you can ask me on my talk page, or place {{helpme}} on your talk page and ask your question there. Please remember to sign your name on talk pages by clicking

or by typing four tildes "~~~~"; this will automatically produce your name and the date. If you are already excited about Wikipedia, you might want to consider being "adopted" by a more experienced editor or joining a WikiProject to collaborate with others in creating and improving articles of your interest. Click here for a directory of all the WikiProjects. Finally, please do your best to always fill in the edit summary field when making edits to pages. Happy editing! JBchrch (talk) 17:05, 25 March 2021 (UTC)[reply]

Getting Started
Introduction • Contributing to Wikipedia • Your first article The five pillars of Wikipedia • Simplified ruleset How to: edit a page • upload an image
Getting Help
Get help at the Teahouse Frequently Asked Questions Where to ask questions Department directory Request administrator attention
Policies and Guidelines
Neutral point of view • Verifiability • No original research Reliable sources • Citing sources • Content guidelines What Wikipedia is not • Biographies of living persons Manual of Style (Simplified) • Three-revert rule Copyrights • Non-free content • Image use policy External links • Spam • Vandalism • Sockpuppetry Deletion policy • Conflict of interest • Notability

The Community
Community Portal • Adopt-a-user program Assume good faith • Civility • Etiquette No personal attacks • Resolving disputes Build consensus • Village pump IRC channels • Mailing lists The Signpost (Wikipedia's newspaper)
Things to do
Task Center • Be bold in editing Maintenance • Peer review • Requested articles Join a WikiProject • Translating articles Cleaning up: General • Copy editing • Vandalism
Miscellaneous
Categories • Disambiguation • Stubs User pages • Talk pages Useful templates • Tools • User scripts

ArbCom 2021 Elections voter message

Hello! Voting in the 2021 Arbitration Committee elections is now open until 23:59 (UTC) on Monday, 6 December 2021. All eligible users are allowed to vote. Users with alternate accounts may only vote once.

The Arbitration Committee is the panel of editors responsible for conducting the Wikipedia arbitration process. It has the authority to impose binding solutions to disputes between editors, primarily for serious conduct disputes the community has been unable to resolve. This includes the authority to impose site bans, topic bans, editing restrictions, and other measures needed to maintain our editing environment. The arbitration policy describes the Committee's roles and responsibilities in greater detail.

If you wish to participate in the 2021 election, please review the candidates and submit your choices on the voting page. If you no longer wish to receive these messages, you may add {{NoACEMM}} to your user talk page. MediaWiki message delivery (talk) 01:04, 23 November 2021 (UTC)[reply]

"O-Cresyl glycidyl ether (o-CGE)" listed at Redirects for discussion

An editor has identified a potential problem with the redirect O-Cresyl glycidyl ether (o-CGE) and has thus listed it for discussion. This discussion will occur at Wikipedia:Redirects for discussion/Log/2022 April 11#O-Cresyl glycidyl ether (o-CGE) until a consensus is reached, and anyone, including you, is welcome to contribute to the discussion. DMacks (talk) 06:51, 11 April 2022 (UTC)[reply]

ArbCom 2022 Elections voter message

Hello! Voting in the 2022 Arbitration Committee elections is now open until 23:59 (UTC) on Monday, 12 December 2022. All eligible users are allowed to vote. Users with alternate accounts may only vote once.

The Arbitration Committee is the panel of editors responsible for conducting the Wikipedia arbitration process. It has the authority to impose binding solutions to disputes between editors, primarily for serious conduct disputes the community has been unable to resolve. This includes the authority to impose site bans, topic bans, editing restrictions, and other measures needed to maintain our editing environment. The arbitration policy describes the Committee's roles and responsibilities in greater detail.

If you wish to participate in the 2022 election, please review the candidates and submit your choices on the voting page. If you no longer wish to receive these messages, you may add {{NoACEMM}} to your user talk page. MediaWiki message delivery (talk) 01:50, 29 November 2022 (UTC)[reply]

I have sent you a note about a page you started

Hello, Innerstream. Thank you for your work on Fipravirimat. User:SunDawn, while examining this page as a part of our page curation process, had the following comments:

Thank you for creating the article!

To reply, leave a comment here and begin it with {{Re|SunDawn}}. Please remember to sign your reply with ~~~~. (Message delivered via the Page Curation tool, on behalf of the reviewer.)

✠ SunDawn ✠ (contact) 06:08, 4 February 2023 (UTC)[reply]

Ways to improve Resmetiron

Hello, Innerstream,

Thank you for creating Resmetiron.

I have tagged the page as having some issues to fix, as a part of our page curation process and note that:

Needs more verifiable sources to establish notability

The tags can be removed by you or another editor once the issues they mention are addressed. If you have questions, leave a comment here and begin it with {{Re|Ppt91}}. Remember to sign your reply with ~~~~. For broader editing help, please visit the Teahouse.

Delivered via the Page Curation tool, on behalf of the reviewer.

Ppt91 (talk) 00:11, 8 February 2023 (UTC)[reply]

Keanumycins

Hi, thanks for the structures of the keanumycins A-C and uploading images of them. Do you happen to have the SMILES or MDL molfiles of the drawings? Btw, what made you decide on the double bond E/Z in the bottom of the drawing? Because when I read the article, they draw it as undefined. Egon Willighagen (talk) 07:26, 5 March 2023 (UTC)[reply]

@Egon Willighagen: It looks like I should have drawn the structures in a way that shows that double bond as having undefined stereochemistry. I'll make the necessary corrections to the images shorty. Thanks for catching that. Here are the SMILES for the three compounds (though they still have the stereochem error that you note).

A:
CCCCCCCCCCCC[C@@H](O)[C@@H](O)CC(=O)N[C@@H](CO)C(=O)N[C@H](CCN)C(=O)NCC(=O)N[C@H](CCO)C(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@H](C)O)C(=O)N\C(=C/C)C(=O)N[C@@H]([C@H](O)C(O)=O)C(=O)N[C@@H]([C@H](O)CCl)C(O)=O
B:
CCCCCCCCCCCCC[C@@H](O)CC(=O)N[C@@H](CO)C(=O)N[C@H](CCN)C(=O)NCC(=O)N[C@H](CCO)C(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@H](C)O)C(=O)N\C(=C/C)C(=O)N[C@@H]([C@H](O)C(O)=O)C(=O)N[C@@H]([C@H](O)CCl)C(O)=O
C:
CCCCCCCCCCCC[C@@H](O)[C@@H](O)CC(=O)N[C@@H](CO)C(=O)N[C@H](CC=N)C(=O)NCC(=O)N[C@H](CCO)C(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@H](C)O)C(=O)N\C(=C/C)C(=O)N[C@@H]([C@H](O)C(O)=O)C(=O)N[C@@H]([C@H](O)CCl)C(O)=O

Innerstream (talk) 14:20, 7 March 2023 (UTC)[reply]

I have now updated the three images. Innerstream (talk) 14:57, 12 March 2023 (UTC)[reply]

Really?

Re: NaOTs and NaO3SPh. What is now depicted is harmless, and such representations will appeal to general readers. The components would separate upon solvation with water, etc. But the article is not about solvates. True, Na+ is often naked.... inside a mass spectrometer.--Smokefoot (talk) 20:12, 18 March 2023 (UTC)[reply]

@Smokefoot: Any time one is depicting the structure of a chemical compound as a two-dimensional line drawing, some details of structure are not going to be conveyed easily. Therefore certain conventions have evolved so that the depictions are understood the same way by different individuals. If you would like to go by what will "appeal to general readers", I think the depiction of a sodium sulfonate as an anion/cation pair will be the most well understood because it is consistent with standard convention. For example, look at the hundreds of files in w:commons:Category:Sodium sulfonates and its subcategories. You would be hard pressed to find any example of a sodium sulfonate depicted with a solid line between oxygen and sodium, which by convention indicates a fully covalent bond. However, if you feel strongly that the original images in those two articles are better, I won't object if you restore them. Also, I removed the disputed template for those images because that template seem best suited for uncontested situations. Innerstream (talk) 21:04, 18 March 2023 (UTC)[reply]

Thanks for taking the time to write a response. No big deal. I confess to be slightly preoccupied by non-nakedness of ions, and very sick of people drawing computer images that show naked little spheres for ions. But you are probably correct about conventions as well as the compromises we all make with drawings. --Smokefoot (talk) 23:13, 18 March 2023 (UTC)[reply]

Lysine acetylsalicylate

Thanks for the drugbox! The image of the lysine component is missing a carbon in its side-chain. DMacks (talk) 20:42, 8 June 2023 (UTC)[reply]

@DMacks: Thanks for catching that. Since you're a Commons administrator, can you please delete File:Lysine acetylsalicylate.svg and File:Lysine acetylsalicylate v2.svg. They are both incorrect and there is already a correct alternative. Innerstream (talk) 12:54, 9 June 2023 (UTC)[reply]

Done. DMacks (talk) 14:17, 10 June 2023 (UTC)[reply]

I have sent you a note about a page you started

Hello, Innerstream. Thank you for your work on Simnotrelvir/ritonavir. User:SunDawn, while examining this page as a part of our page curation process, had the following comments:

Thank you for writing the article on Wikipedia! I genuinely appreciate your efforts in creating the article on Wikipedia and expanding the sum of human knowledge in Wikipedia. Wishing you and your family a great day!

To reply, leave a comment here and begin it with {{Re|SunDawn}}. Please remember to sign your reply with ~~~~. (Message delivered via the Page Curation tool, on behalf of the reviewer.)

✠ SunDawn ✠ (contact) 03:40, 9 October 2023 (UTC)[reply]

ArbCom 2023 Elections voter message

Hello! Voting in the 2023 Arbitration Committee elections is now open until 23:59 (UTC) on Monday, 11 December 2023. All eligible users are allowed to vote. Users with alternate accounts may only vote once.

The Arbitration Committee is the panel of editors responsible for conducting the Wikipedia arbitration process. It has the authority to impose binding solutions to disputes between editors, primarily for serious conduct disputes the community has been unable to resolve. This includes the authority to impose site bans, topic bans, editing restrictions, and other measures needed to maintain our editing environment. The arbitration policy describes the Committee's roles and responsibilities in greater detail.

If you wish to participate in the 2023 election, please review the candidates and submit your choices on the voting page. If you no longer wish to receive these messages, you may add {{NoACEMM}} to your user talk page. MediaWiki message delivery (talk) 00:55, 28 November 2023 (UTC)[reply]

A Nanokid for you!

	A Nanokid for you!
	Thanks for creating Bunamidine and improving coverage of (bio)chemistry articles on Wikipedia! Happy editing! Justi yaya 16:20, 13 January 2024 (UTC)[reply]

Cute kid. Thank you! Innerstream (talk) 23:42, 13 January 2024 (UTC)[reply]

Hey

I noticed that you've been editing some health-related articles recently. A bunch of us hang out at Wikipedia talk:WikiProject Medicine. It's a good place to ask questions about good sources for medical content and appropriate writing style. There's also a much smaller group at Wikipedia talk:WikiProject Veterinary medicine. Please consider putting the page on your watchlist, or stop by to say hello some time. WhatamIdoing (talk) 19:07, 16 January 2024 (UTC)[reply]

Thanks for the suggestion. I'll watchlist those pages. Innerstream (talk) 02:32, 17 January 2024 (UTC)[reply]

Thanks! WhatamIdoing (talk) 02:35, 17 January 2024 (UTC)[reply]

I have sent you a note about a page you started

Hello, Innerstream. Thank you for your work on Sulanemadlin. Klbrain, while examining this page as a part of our page curation process, had the following comments:

A chemical entity with an interesting structure that has entered clinical trials is certainly work including. It's a short article, for now, but focussed. Adding a little more 'bad news' about the side effects of the drug would also be helpful (I've started that).

To reply, leave a comment here and begin it with {{Re|Klbrain}}. Please remember to sign your reply with ~~~~. (Message delivered via the Page Curation tool, on behalf of the reviewer.)

Klbrain (talk) 16:52, 18 April 2024 (UTC)[reply]

I have sent you a note about a page you started

Hi Innerstream. Thank you for your work on Hyzetimibe. Another editor, Klbrain, has reviewed it as part of new pages patrol and left the following comment:

Thanks for helpfully adding this stub; it's helpful to have, particularly for a compound that is in clinical used (at least in China). The CAS number didn't work for me, and I couldn't find an entry on searching that database.

To reply, leave a comment here and begin it with {{Re|Klbrain}}. (Message delivered via the Page Curation tool, on behalf of the reviewer.)

Klbrain (talk) 13:30, 24 April 2024 (UTC)[reply]

@Klbrain: Thanks for reviewing the articles I recently created. In the template {{Infobox drug}}, the "CAS_number" field links to the Common Chemistry website, which consists of only a small subset of all CAS numbers and therefore it is not a good source for verification of CAS numbers. I have verified this particular CAS number (and all other CAS numbers I have added) directly with the Chemical Abstracts Service database itself. Innerstream (talk) 18:20, 24 April 2024 (UTC)[reply]

Thanks for checking, and for letting me know about the unreliability of the Common Chemistry website for checking CAS numbers! Klbrain (talk) 20:25, 24 April 2024 (UTC)[reply]

I have sent you a note about a page you started

Hi Innerstream. Thank you for your work on Surufatinib. Another editor, Klbrain, has reviewed it as part of new pages patrol and left the following comment:

Another helpful stub, but again the CAS number doesn't seem right - and a search doesn't find the compound there.

To reply, leave a comment here and begin it with {{Re|Klbrain}}. (Message delivered via the Page Curation tool, on behalf of the reviewer.)

Klbrain (talk) 13:33, 24 April 2024 (UTC)[reply]

I have sent you a note about a page you started

Hi Innerstream. Thank you for your work on Orelabrutinib. Another editor, Klbrain, has reviewed it as part of new pages patrol and left the following comment:

Another well-warranted stub. It might also be helpful to add some of these to Wikidata, if you're in the mood!

To reply, leave a comment here and begin it with {{Re|Klbrain}}. (Message delivered via the Page Curation tool, on behalf of the reviewer.)

Klbrain (talk) 13:36, 24 April 2024 (UTC)[reply]

I have sent you a note about a page you started

Hi Innerstream. Thank you for your work on Hetrombopag. Another editor, Klbrain, has reviewed it as part of new pages patrol and left the following comment:

Thanks for helpfully starting this page. As it is a therapeutically used drug, it's best to use it INN; that's also the name that the references mostly use. There is plenty of scope for expansion as its use develops over time.

To reply, leave a comment here and begin it with {{Re|Klbrain}}. (Message delivered via the Page Curation tool, on behalf of the reviewer.)

Klbrain (talk) 10:30, 6 May 2024 (UTC)[reply]

@Klbrain: Are you sure hetrombopag is the INN? The FDA seems to think the INN is rafutrombopag. If you click on the UNII link in the infobox, it takes you to a FDA webpage for the drug (https://precision.fda.gov/uniisearch/srs/unii/9WGT51BDDL) with the synonym "RAFUTROMBOPAG [INN]". Can you have a second look? Thanks. Innerstream (talk) 13:55, 6 May 2024 (UTC)[reply]

Interesting; IUPHAR, which sticks to INN, uses hetrombopag, and given that the peer-reviewed sources are using it too ... USFDA uses UNII names, which aren't necessarily INNs. Klbrain (talk) 18:56, 6 May 2024 (UTC)[reply]

I bet this is a case where the generic name has been changed during the course of drug development and/or different naming organizations have settled on different names. But I suppose the article is fine titled either way, with the appropriate redirects. Cheers, Innerstream (talk) 19:58, 6 May 2024 (UTC)[reply]

I have sent you a note about a page you started

Hi Innerstream. Thank you for your work on Disitamab vedotin. Another editor, Klbrain, has reviewed it as part of new pages patrol and left the following comment:

Thanks for creating this page for a therapeutic compound in clinical use. It's appropriately marked as a stub, but can grow from here.

To reply, leave a comment here and begin it with {{Re|Klbrain}}. (Message delivered via the Page Curation tool, on behalf of the reviewer.)

Klbrain (talk) 19:22, 19 July 2024 (UTC)[reply]

Autopatrolled granted

Hi Innerstream, I just wanted to let you know that I have added the autopatrolled user right to your account. This means that pages you create will automatically be marked as 'reviewed', and no longer appear in the new pages feed. Autopatrolled is assigned to prolific creators of articles, where those articles do not require further review, and may have been requested on your behalf by someone else. It doesn't affect how you edit; it is used only to manage the workload of new page patrollers.

Since the articles you create will no longer be systematically reviewed by other editors, it is important that you maintain the high standard you have achieved so far in all your future creations. Please also try to remember to add relevant WikiProject templates, stub tags, categories, and incoming links to them, if you aren't already in the habit; user scripts such as Rater and StubSorter can help with this. As you have already shown that you have a strong grasp of Wikipedia's core content policies, you might also consider volunteering to become a new page patroller yourself, helping to uphold the project's standards and encourage other good faith article writers.

Feel free to leave me a message if you have any questions. Happy editing! HJ Mitchell | Penny for your thoughts? 15:07, 26 August 2024 (UTC)[reply]

Thank you. Innerstream (talk) 15:00, 27 August 2024 (UTC)[reply]